Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Authors: Stewart, Tessandra; Sossi, Vesna; Aasly, Jan O; Wszolek, Zbigniew K; Uitti, Ryan J; Hasegawa, Kazuko; Yokoyama, Teruo; Zabetian, Cyrus P; Leverenz, James B; Stoessl, Alexander Jon; Wang, Yu; Ginghina, Carmen; Liu, Changqin; Cain, Kevin C; Auinger, Peggy; Kang, Un Jung; Jensen, Poul Henning; Shi, Min; Zhang, Jing

Published In Acta Neuropathol Commun, (2015 Jan 31)

Abstract: α-Synuclein (α-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers).Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages.The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally.

PubMed ID: 25637461 Exiting the NIEHS site

MeSH Terms: Aged; Biomarkers/cerebrospinal fluid*; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Mutation; Parkinson Disease/cerebrospinal fluid*; Parkinson Disease/diagnostic imaging; Parkinson Disease/metabolism; Parkinson Disease/physiopathology*; Phosphorylation; Positron-Emission Tomography; Protein-Serine-Threonine Kinases/genetics; ROC Curve; Severity of Illness Index; Statistics as Topic; Time Factors; alpha-Synuclein/cerebrospinal fluid*; alpha-Synuclein/metabolism

to Top